Cargando…

Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia

BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Haroun-Izquierdo, Alvaro, Vincenti, Marianna, Netskar, Herman, van Ooijen, Hanna, Zhang, Bin, Bendzick, Laura, Kanaya, Minoru, Momayyezi, Pouria, Li, Shuo, Wiiger, Merete Thune, Hoel, Hanna Julie, Krokeide, Silje Zandstra, Kremer, Veronika, Tjonnfjord, Geir, Berggren, Stéphanie, Wikström, Kristina, Blomberg, Pontus, Alici, Evren, Felices, Martin, Önfelt, Björn, Höglund, Petter, Valamehr, Bahram, Ljunggren, Hans-Gustaf, Björklund, Andreas, Hammer, Quirin, Kveberg, Lise, Cichocki, Frank, Miller, Jeffrey S, Malmberg, Karl-Johan, Sohlberg, Ebba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628692/
https://www.ncbi.nlm.nih.gov/pubmed/36319065
http://dx.doi.org/10.1136/jitc-2022-005577
_version_ 1784823242473603072
author Haroun-Izquierdo, Alvaro
Vincenti, Marianna
Netskar, Herman
van Ooijen, Hanna
Zhang, Bin
Bendzick, Laura
Kanaya, Minoru
Momayyezi, Pouria
Li, Shuo
Wiiger, Merete Thune
Hoel, Hanna Julie
Krokeide, Silje Zandstra
Kremer, Veronika
Tjonnfjord, Geir
Berggren, Stéphanie
Wikström, Kristina
Blomberg, Pontus
Alici, Evren
Felices, Martin
Önfelt, Björn
Höglund, Petter
Valamehr, Bahram
Ljunggren, Hans-Gustaf
Björklund, Andreas
Hammer, Quirin
Kveberg, Lise
Cichocki, Frank
Miller, Jeffrey S
Malmberg, Karl-Johan
Sohlberg, Ebba
author_facet Haroun-Izquierdo, Alvaro
Vincenti, Marianna
Netskar, Herman
van Ooijen, Hanna
Zhang, Bin
Bendzick, Laura
Kanaya, Minoru
Momayyezi, Pouria
Li, Shuo
Wiiger, Merete Thune
Hoel, Hanna Julie
Krokeide, Silje Zandstra
Kremer, Veronika
Tjonnfjord, Geir
Berggren, Stéphanie
Wikström, Kristina
Blomberg, Pontus
Alici, Evren
Felices, Martin
Önfelt, Björn
Höglund, Petter
Valamehr, Bahram
Ljunggren, Hans-Gustaf
Björklund, Andreas
Hammer, Quirin
Kveberg, Lise
Cichocki, Frank
Miller, Jeffrey S
Malmberg, Karl-Johan
Sohlberg, Ebba
author_sort Haroun-Izquierdo, Alvaro
collection PubMed
description BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)(+)NKG2C(+) adaptive NK cells to maximize missing-self reactivity. METHODS: We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. RESULTS: ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45(dim) blast subtypes. CONCLUSIONS: These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability.
format Online
Article
Text
id pubmed-9628692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96286922022-11-03 Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia Haroun-Izquierdo, Alvaro Vincenti, Marianna Netskar, Herman van Ooijen, Hanna Zhang, Bin Bendzick, Laura Kanaya, Minoru Momayyezi, Pouria Li, Shuo Wiiger, Merete Thune Hoel, Hanna Julie Krokeide, Silje Zandstra Kremer, Veronika Tjonnfjord, Geir Berggren, Stéphanie Wikström, Kristina Blomberg, Pontus Alici, Evren Felices, Martin Önfelt, Björn Höglund, Petter Valamehr, Bahram Ljunggren, Hans-Gustaf Björklund, Andreas Hammer, Quirin Kveberg, Lise Cichocki, Frank Miller, Jeffrey S Malmberg, Karl-Johan Sohlberg, Ebba J Immunother Cancer Immune Cell Therapies and Immune Cell Engineering BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)(+)NKG2C(+) adaptive NK cells to maximize missing-self reactivity. METHODS: We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. RESULTS: ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45(dim) blast subtypes. CONCLUSIONS: These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability. BMJ Publishing Group 2022-11-01 /pmc/articles/PMC9628692/ /pubmed/36319065 http://dx.doi.org/10.1136/jitc-2022-005577 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Immune Cell Therapies and Immune Cell Engineering
Haroun-Izquierdo, Alvaro
Vincenti, Marianna
Netskar, Herman
van Ooijen, Hanna
Zhang, Bin
Bendzick, Laura
Kanaya, Minoru
Momayyezi, Pouria
Li, Shuo
Wiiger, Merete Thune
Hoel, Hanna Julie
Krokeide, Silje Zandstra
Kremer, Veronika
Tjonnfjord, Geir
Berggren, Stéphanie
Wikström, Kristina
Blomberg, Pontus
Alici, Evren
Felices, Martin
Önfelt, Björn
Höglund, Petter
Valamehr, Bahram
Ljunggren, Hans-Gustaf
Björklund, Andreas
Hammer, Quirin
Kveberg, Lise
Cichocki, Frank
Miller, Jeffrey S
Malmberg, Karl-Johan
Sohlberg, Ebba
Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title_full Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title_fullStr Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title_full_unstemmed Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title_short Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
title_sort adaptive single-kir(+)nkg2c(+) nk cells expanded from select superdonors show potent missing-self reactivity and efficiently control hla-mismatched acute myeloid leukemia
topic Immune Cell Therapies and Immune Cell Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628692/
https://www.ncbi.nlm.nih.gov/pubmed/36319065
http://dx.doi.org/10.1136/jitc-2022-005577
work_keys_str_mv AT harounizquierdoalvaro adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT vincentimarianna adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT netskarherman adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT vanooijenhanna adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT zhangbin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT bendzicklaura adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT kanayaminoru adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT momayyezipouria adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT lishuo adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT wiigermeretethune adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT hoelhannajulie adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT krokeidesiljezandstra adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT kremerveronika adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT tjonnfjordgeir adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT berggrenstephanie adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT wikstromkristina adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT blombergpontus adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT alicievren adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT felicesmartin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT onfeltbjorn adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT hoglundpetter adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT valamehrbahram adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT ljunggrenhansgustaf adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT bjorklundandreas adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT hammerquirin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT kveberglise adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT cichockifrank adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT millerjeffreys adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT malmbergkarljohan adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia
AT sohlbergebba adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia